Answers are grounded in this paper and cite their sources.
Immunologically "cold" tumors are unresponsive to immune checkpoint blockade and adoptive cell therapies. Thisunresponsiveness has been attributed to factors such as limited antigen presentation, abnormal vasculature, metabolic constraints, suppressive myeloid and regulatory networks, and the exclusion of effector lymphocytes. Engineered nanobiomaterials have recently emerged as versatile immunoengineering platforms capable of modulating these barriers within the tumor microenvironment (TME). This narrative review summarizes recent preclinical and early clinical advances demonstrating how rationally designed nanobiomaterials can induce immunogenic cell death, activate innate immune sensing pathways, remodel immunosuppressive TMEs, enhance dendritic cell priming, and promote T-cell infiltration and memory formation. Through these mechanisms, nanobiomaterials have the capacity to reprogram cold tumors into immunotherapy-responsive microenvironments. The present study also evaluates the translational potential of nano-enabled immunotherapies and then discusses the current challenges related to targeting specificity, safety, and scalability. Finally, we highlight future directions focused on mechanism-driven design, integration with cell-based immunotherapies, and the incorporation of clinically relevant immune profiling strategies to improve therapeutic outcomes.
No takes yet. Share an insight, caveat, or question.
Farah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: